Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06962280 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 465
- Enrollment target
- 20
- Study locations
NCT06962280 is a Phase 3 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 465 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (43% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06962280, a Phase 3 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 465 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
Texas
- Velocity Clinical Research, Dallas - Dallas
- Juno Research - Houston
- Southern Endocrinology Associates - Mesquite
- Texas Diabetes & Endocrinology, P.A. - Round Rock
- San Antonio Clinical Trials - San Antonio
- Texas Valley Clinical Research - Weslaco
California
- Kaiser Permanente Bonita Medical Offices - Bonita
- AMCR Institute - Escondido
- Mary & Dick Allen Diabetes Center - Newport Beach
- University Clinical Investigators, Inc. - Tustin
Missouri
- Clinical Research Professionals - Chesterfield
- Clinvest Headlands Llc - Springfield
Other
- Buenos Aires Macula S.A - Buenos Aires
- Stat Research S.A. - Buenos Aires
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Florida
- Metabolic Research Institute, Inc. - West Palm Beach
Iowa
- Iowa Diabetes and Endocrinology Research Center - West Des Moines
Minnesota
- HealthPartners Institute dba International Diabetes Center - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 465 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06962280
The ClinicalTrials.gov registry entry for NCT06962280 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 465 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (43% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06962280 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Texas, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT06962280 about?
NCT06962280 is a clinical study titled "A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight". The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
What is the current status of trial NCT06962280?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 465 participants. The study started on 2025-05-12. Estimated completion is 2027-07.
What conditions does trial NCT06962280 study?
This clinical trial studies the following conditions: Obesity, Overweight, Type 1 Diabetes.
What interventions are being tested in trial NCT06962280?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT06962280?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06962280 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Iowa, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.